2017版国家医保药品目录限定支付情况分析  

Analysis on Reimbursement Limits of National Basic Medical Insurance Drug List 2017

作　　者：高楠[1] 徐伟[1] 

机构地区：[1]中国药科大学国际医药商学院,南京211198

出　　处：《中国卫生经济》2018年第1期48-50,共3页Chinese Health Economics

摘　　要：目的:分析《人力资源社会保障部关于印发国家基本医疗保险、工伤保险和生育保险药品目录(2017年版)》(以下简称《2017版药品目录》)限定支付情况。方法:通过归纳分析、对比分析等方法总结限定支付类型并分析所涉及的药品在数目、类别、适应症等方面的特征。结果:《2017版药品目录》对903个品种实行限定支付,包括险种限制、统筹基金使用范围限制、二线用药限制和适应症限制等,各限制具体情况体现《2017版药品目录》"宽进严管理"的调整思路。结论:2017版目录的限定较为规范,理论上保证了临床的合理用药和医保基金的高效使用。Objective： Analyzing reimbursement limits of National Basic Medical Insurance Drug List 2017. Methods： The kinds of reimbursement limits and characters of relative drugs inquantities, categories and indications were concluded through methods of induction and correlation. Results： 903 drugs were limited in National Basic Medical Insurance Drug Li.st 2017, involving categories of insurance, serviceable range of pooling funds, second-line use and indications. Conclusion： The reimbursement limits were normative, ensuring rational drug use and efficiency of medical insurance funds.

关 键 词：医保药品 药品目录 医保基金 限定支付 

分 类 号：R1-9[医药卫生—公共卫生与预防医学] F840.613[经济管理—保险]